HIV testing
Policy Brief
July 2015
Internally displaced children are twice invisible in global and national data. First, because internally displaced people (IDPs) of all ages are often unaccounted for. Second, because age-disaggregation of any kind of data is limited, and even more so for IDPs.
Planning adequate responses to meet... the needs of internally displaced children, however, requires having at least a sense of how many there are and where they are. This report presents the first estimates of the number of children living in internal displacement triggered by conflict and violence at the global, regional and national levels.
more
PLOS Medicine | DOI:10.1371/journal.pmed.1002088 August 23, 2016
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
Technical Report
AIDS Medicines and diagnostics service
July 2015
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
National HIV curriculum
You can always find the most up to date version of this document at
https://www.hiv.uw.edu/go/co-occurring-conditions/opportunistic-infections-prevention/coreconcept/all
Accelerating HIV prevention to reduce new infections by 75%
Rutstein SE et al. Journal of the International AIDS Society 2017, 20:21579 http://www.jiasociety.org/index.php/jias/article/view/21579 | http://dx.doi.org/10.7448/IAS.20.1.21579
WHO recommends replacing western blotting and line immunoassays with simpler tests in HIV testing services. These simpler tests include rapid diagnostic tests (RDTs) that can be used at the point-of-care, and enzyme immunoassays (EIAs).
These tests get results to the client faster, produce accura...te results more often, cost less, can be performed by various cadres of health providers, and can thus facilitate greater access and uptake of HIV testing services among those who need it most.
more
Plan Stratégique de Developpement des Ressources Humaines du Secteur Santé 2009-2018
Annuaire des Statistiques Sanitaires
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.
more